Portal de Periódicos da CAPES

Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis

2023; Elsevier BV; Volume: 35; Issue: 3 Linguagem: Inglês

10.1016/j.annonc.2023.11.013

1569-8041

Josep M. Piulats, Claire Watkins, Marcel Costa-García, L. Del Carpio, Sophie Piperno‐Neumann, Piotr Rutkowski, Jessica C. Hassel, Enrique Espinosa, Luis de la Cruz‐Merino, Sebastian Ochsenreither, A.N. Shoushtari, Marlana Orloff, April K.S. Salama, Howard Goodall, Jean‐François Baurain, Paul Nathan,

Bladder and Urothelial Cancer Treatments

Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator's choice (82% pembrolizumab) in a randomized, phase III trial (IMCgp100-202; N = 378) in untreated metastatic uveal melanoma (mUM). The 1-year OS rates for tebentafusp and pembrolizumab were 73% and 59%, respectively. In the single-arm GEM1402 (N = 52), the 1-year OS rate for nivolumab plus ipilimumab (N+I) in mUM was 52%. Due to limitations in conducting randomized trials in mUM, we compared OS on tebentafusp or pembrolizumab (IMCgp100-202) to N+I (GEM1402) in untreated mUM using propensity scoring methods.